Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Non-Current Assets came in at $141.3 billion in Q2 2026, up 1.73% year-over-year from $138.9 billion in Q2 2025, and little changed quarter-over-quarter from $141.7 billion in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Non-Current Assets (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Non-Current Assets across 18 years of filings, most recently posting $141.3 billion for Q2 2026.
- In Q2 2026, Non-Current Assets rose 1.73% year-over-year to $141.3 billion; the TTM figure through Jun 2026 stood at $564.8 billion (up 10.69% YoY), while the FY2025 annual figure was $143.6 billion, up 15.6% from the prior year.
- Non-Current Assets came in at $141.3 billion for Q2 2026 at Johnson & Johnson, roughly flat from $141.7 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $143.6 billion in Q4 2025 to a low of $109.9 billion in Q4 2022.
- Average Non-Current Assets over 5 years is $126.2 billion, with a median of $124.2 billion recorded in 2024.
- Year-over-year, Non-Current Assets declined 13.64% in 2023 and increased 16.05% in 2026.
- Over 5 years, Non-Current Assets stood at $109.9 billion in 2022, then increased by 3.8% to $114.1 billion in 2023, then grew by 8.9% to $124.2 billion in 2024, then advanced by 15.6% to $143.6 billion in 2025, then fell by 1.6% to $141.3 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $141.3 billion in Q2 2026, $141.7 billion in Q1 2026, and $143.6 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 159.77 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 113.37 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 294.93 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1.85 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 3.74 Bn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 3.72 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 141.29 Bn |
| Mar 29, 2026 | 141.72 Bn |
| Dec 28, 2025 | 143.59 Bn |
| Sep 28, 2025 | 138.21 Bn |
| Jun 29, 2025 | 138.89 Bn |
| Mar 30, 2025 | 122.12 Bn |
| Dec 29, 2024 | 124.21 Bn |
| Sep 29, 2024 | 125.04 Bn |
| Jun 30, 2024 | 123.27 Bn |
| Mar 31, 2024 | 114.96 Bn |
| Dec 31, 2023 | 114.06 Bn |
| Oct 1, 2023 | 112.36 Bn |
| Jul 2, 2023 | 131.12 Bn |
| Apr 2, 2023 | 131.58 Bn |
| Jan 1, 2023 | 132.08 Bn |
| Oct 2, 2022 | 109.89 Bn |
| Jul 3, 2022 | 113.88 Bn |
| Apr 3, 2022 | 117.93 Bn |
| Jan 2, 2022 | 121.04 Bn |
| Oct 3, 2021 | 119.34 Bn |